Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on July 2, 2019, with the earliest event reported on July 8, 2019. The filing discloses significant changes in executive leadership and board composition.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
- New CEO Base Salary: $573,710 annually.
- Target Cash Incentive: Up to 150% of base salary (commencing fiscal year 2020).
- Equity Grants (James Green):
- 243,072 Restricted Stock Units (RSUs) vesting in two years.
- 202,875 RSUs vesting in one year (satisfying minimum 2019 bonus).
- 418,360 RSUs with market condition vesting (relative TSR vs. NASDAQ Biotechnology).
- 418,360 RSUs vesting in four equal annual installments starting January 1, 2020.
Material Changes
The primary material change is the departure of Jeffrey A. Duchemin and the appointment of James Green.
- Departure: Jeffrey A. Duchemin resigned as President, Chief Executive Officer, and Director effective July 7, 2019. A Separation and Release Agreement was executed, effective July 10, 2019, subject to revocation rights.
- Appointment: James Green was appointed President and Chief Executive Officer effective July 8, 2019.
- Board Changes: James Green continues as Chairman of the Board but as a non-independent director and will not serve on standing committees. Bertrand Loy was appointed Lead Independent Director.
Outlook, Risks, and Unusual Items
The filing outlines the terms of the new CEO's employment agreement, including severance and change-in-control provisions.
- Employment Term: Two-year initial term with automatic two-year extensions unless notice is given 90 days prior.
- Termination Benefits: The agreement provides for accrued salary, unused vacation, and earned bonuses upon termination without cause, for good reason, death, disability, or change-in-control. Severance and acceleration of vesting are subject to the executive signing a general release of claims.
- Regulatory Compliance: The agreement includes customary best net/modified economic cutback provisions regarding Section 280G of the Internal Revenue Code.
Investor Verification Checklist
- Verify the specific financial terms of the Separation and Release Agreement for Jeffrey Duchemin (Exhibit 10.2).
- Review the full Employment Agreement for James Green (Exhibit 10.1) to understand specific performance metrics for the 150% cash incentive and market condition RSUs.
- Confirm the impact of the leadership transition on the company's strategic direction as detailed in the press release (Exhibit 99.1).
- Monitor the vesting schedule of the approximately 1.28 million total RSUs granted to the new CEO.